Eli Lilly and Company (NYSE:LLY) Stock Price Up 2.4% Following Analyst Upgrade

Eli Lilly and Company (NYSE:LLY) shares rose 2.4% during trading on Friday after Jefferies Financial Group raised their price target on the stock from $1,300.00 to $1,330.00. The stock traded as high as $1,070.34 and last traded at $1,066.5890. Approximately 3,464,290 shares were traded during mid-day trading, an increase of 9% from the average daily volume of 3,188,047 shares. The stock had previously closed at $1,041.65.

LLY has been the topic of several other research reports. BMO Capital Markets reiterated an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a report on Thursday, February 5th. Zacks Research downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Daiwa Securities Group lifted their target price on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,220.37.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly reported strong Phase 3 retatrutide results, with substantial weight loss across doses and long-term durability, boosting confidence in its next major obesity franchise. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
• Positive Sentiment: Investors are also reacting to repeated coverage that retatrutide may outperform existing GLP-1 therapies, which could expand Lilly’s lead in the fast-growing weight-loss drug market. Patients on Lilly’s next-gen obesity drug lost 28% of body weight, company says
• Positive Sentiment: Jefferies raised its price target on LLY to $1,330, signaling continued analyst confidence in Lilly’s earnings power and obesity pipeline. Jefferies lifts Eli Lilly price target to 1,330 from 1,300
• Positive Sentiment: Lilly’s new late-stage Foundayo data also showed strong weight-loss results in older adults, adding more support to the company’s broader GLP-1 growth story. Eli Lilly Highlights Positive Late-Stage Foundayo Data At Obesity Conference
• Neutral Sentiment: Lilly is expanding beyond obesity through acquisitions and pipeline development, including a deal for Engage Biologics and new studies in Alzheimer’s and heart failure, which supports long-term diversification but is less immediately market-moving. Eli Lilly’s Engage Biologics Deal Extends Genetic Bets Beyond Obesity Boom

Institutional Trading of Eli Lilly and Company

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in Eli Lilly and Company by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after buying an additional 1,006,885 shares in the last quarter. State Street Corp boosted its position in Eli Lilly and Company by 1.8% in the fourth quarter. State Street Corp now owns 35,361,916 shares of the company’s stock valued at $38,002,744,000 after buying an additional 635,358 shares in the last quarter. Capital Research Global Investors boosted its position in Eli Lilly and Company by 20.9% in the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after buying an additional 4,332,008 shares in the last quarter. Morgan Stanley boosted its position in Eli Lilly and Company by 2.7% in the fourth quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock valued at $16,757,510,000 after buying an additional 407,166 shares in the last quarter. Finally, Capital World Investors boosted its position in Eli Lilly and Company by 0.4% in the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after buying an additional 61,851 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

The stock has a market capitalization of $1.00 trillion, a price-to-earnings ratio of 37.89, a price-to-earnings-growth ratio of 1.11 and a beta of 0.48. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The stock’s 50-day simple moving average is $941.52 and its 200 day simple moving average is $1,003.33.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period in the previous year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts expect that Eli Lilly and Company will post 35.82 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is 24.58%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.